de la Cruz-Ares, SilviaCardelo, Magdalena PGutiérrez-Mariscal, Francisco MTorres-Peña, José DGarcía-Rios, AntonioKatsiki, NikiMalagón, María MLópez-Miranda, JoséPérez-Martínez, PabloYubero-Serrano, Elena M2023-02-082023-02-082020-01-16http://hdl.handle.net/10668/14979Endothelial dysfunction and intima-media thickness of common carotid arteries (IMT-CC) are considered subclinical markers of atherosclerotic cardiovascular disease (ASCVD). Advanced glycation end products (AGEs) are increased in type 2 diabetes mellitus (T2DM) patients, compared with non-diabetics, being implicated in micro- and macrovascular complications. Our aim was to compare serum AGEs levels and subclinical atherosclerotic markers between patients with established and newly diagnosed T2DM. Among 540 patients with T2DM and coronary heart disease from the CORDIOPREV study, 350 patients had established T2DM and 190 patients had newly diagnosed T2DM. Serum levels of AGEs (methylglyoxal (MG) and N-carboxymethyl lysine (CML)) and subclinical atherosclerotic markers (brachial flow-mediated vasodilation (FMD) and IMT-CC) were measured. AGEs levels (all penAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/CORDIOPREVN-carboxymethyl lysineadvanced glycation end productsendothelial dysfunctionflow-mediated vasodilationintima-media thickness of common carotid arteriesmethylglyoxaltype 2 diabetes mellitusBiomarkersCarotid Artery DiseasesCoronary DiseaseCross-Sectional StudiesDiabetes Mellitus, Type 2Diet, HealthyEndothelium, VascularFemaleGlycation End Products, AdvancedHumansLysineMaleMiddle AgedOlive OilPyruvaldehydeSingle-Blind MethodVasodilationresearch article31963378open access10.3390/nu120102382072-6643PMC7019746https://www.mdpi.com/2072-6643/12/1/238/pdf?version=1579747633https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019746/pdf